Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients
Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients
AST welcomes Drs. Kizilbash, Valencia Deray, and Ouellette to discuss the effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients.
- 3:00 PM - 4:00 PM EDT
- Virtual
"Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium"
(Pediatr Transplant. 2024 May;28(3):e14743. doi: 10.1111/petr.14743.)
In this article:
There are scant data on the effect of rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplant recipients with EBV DNAemia. In the largest pediatric kidney transplant recipient case series with EBV DNAemia given rituximab to prevent PTLD, rituximab achieved a short-term reduction in DNA load; however, recurrent DNAemia is common. Read more.
Speaker:
Sarah Kizilbash, MD • University of Minnesota, Minneapolis, MN
Discussant:
Kristen Valencia Deray, MD • Baylor College of Medicine, Houston, TX
Moderator:
Christopher Ouellette, MD • Nationwide Children’s Hospital, Columbus, OH
This AST Journal Club Series webinar is hosted by AST's Infectious Disease (IDCOP) and Pediatric (PCOP) Communities of Practice. All AST Journal Clubs are free but registration is required to attend live.
Advertisements
